| Test | In Range | Out Of Range | Units | Reference |
|---|---|---|---|---|
| Ammonia | 34 H | umol/L | 11 - 32 | |
| Comp Metabolic Pnl | ||||
| Sodium | 138 | mmol/L | 136 - 145 | |
| Potassium | 4.3 | mmol/L | 3.5 - 5.1 | |
| Chloride | 104 | mmol/L | 98 - 107 | |
| Bicarbonate | 26 | mmol/L | 21 - 32 | |
| Anion Gap | 8 | mmol/L | 3 - 12 | |
| Glucose | 100 H | mg/dL | 70 - 99 | |
| BUN | 23 H | mg/dL | 7 - 18.0 | |
| Creatinine | 0.78 | mg/dL | 0.60 - 1.10 | |
| eGFR-Other | 90 | mL/min/1.73 m2 | > 60 | |
| Estimated glomerular filtration rate values are calculated using the CKD-EPI equation. | ||||
| Calcium | 9.2 | mg/dL | 8.5 - 10.1 | |
| Total Protein | 6.8 | g/dL | 6.2 - 8.5 | |
| Albumin | 3.8 | g/dL | 3.4 - 5.0 | |
| Bilirubin, Total | 0.1 | mg/dL | < 1.1 | |
| Alkaline Phosphatase | 65 | U/L | 50 - 136 | |
| AST | L 9 | U/L | 15 - 37 | |
| ALT | 16 | U/L | 0 - 60 | |
| Note New Normal Range | ||||
| Folate, RBC | ||||
| Folate, RBC | 555 | ng/mL | 280 - 791 | |
| Hematocrit | L 31.4 | 40.0 - 52.0 | % | |
| CRP Indflammatory | < 0.5 | mg/L | 0.0 - 8.0 | |
| CRP is useful for recognizing and monitoring inflammatory processes. Units are expressed as mg/L which is 10x classical units of mg/dL. Therefore result of 47 mg/L is equivalent to 4.7 mg/dL. | ||||
| Iron/Iron Binding | ||||
| Iron | 74 | ug/dL | 35 - 150 | |
| Patients receiving I.V. iron therapy preparations show invalid results up to 3 weeks post administration of drug. | ||||
| Iron Binding | 379 | ug/dL | 250 - 450 | |
| Iron Saturation | 20 | % | 20 - 50 | |
| Free T3 | 2.92 | pg/mL | 2.3 - 4.2 | |
| MTHFR, A1298C | ||||
| MTHFR, A1298C | Neg | Neg | ||
| NEGATIVE for A1298C MUTATION DNA testing indicates this individual is negative for the methylenetetrahydrofolate reductase (MTHFR) A1298C polymorphism. Other causes of elevated homocysteine levels, coronary heart disease, or thrombosis cannot be excluded. This negative result does not rule out the presence of other mutations within the MTHFR gene, such as C677T. Other genetic and environmental factors (e.g., dietary folate levels) effect homocysteine levels. | ||||
| Method | These mutations are detected by linear signal amplification using Invader Technology. It is a novel, homogenous platform that can analyze DNA with prior amplification of the target. It uses oligonucleotides that bind to the target in a sequence specific manner and an enzyme that cleaves in a structure specific manner. A standard fluorescence microtiter plate reader can readily detect the signals generated in the assay. Since genetic variation and other factors can affect the accuracy of direct mutation testing, these results should be interpreted in the light of clinical and familial data. | |||
| MTHFR, C677T | ||||
| Heterozygous | Neg | |||
| Heterozygous for C677T Mutation | DNA testing indicates this individual is heterozygous for the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism. This is associated with reduced levels of MTHFR enzyme activity, but no increase in plasma homocysteine levels. Heterozygosity has not been correlated with coronary disease nor venous thrombosis. The C677T mutation is common in the general population. Homozygosity has been correlated with intermediate and mild hyperhomocysteinemia. Consider DNA testing and genetic counseling for other at risk family members. This test does not rule out other mutations in the MTHFR gene, such as A1298C. C677T/A1298C compound heterozygotes have been reported to have increased risk for hyperhomocysteinemia and neural tube defects in some populations, but not all populations. Other genetic and environmental factors (e.g., dietary folate levels) affect homocysteine levels. | |||
| Method | These mutations are detected by linear signal amplification using Invader Technology. It is a novel, homogenous platform that can analyze DNA with prior amplification of the target. It uses oligonucleotides that bind to the target in a sequence specific manner and an enzyme that cleaves in a structure specific manner. A standard fluorescence microtiter plate reader can readily detect the signals generated in the assay. Since genetic variation and other factors can affect the accuracy of direct mutation testing, these results should be interpreted in the light of clinical and familial data. | |||
| Free T4 | 1.08 | ng/dL | 0.80 - 1.80 | |
| Transferrin | 296 | mg/dL | 200 - 360 | |
| TSH | 0.42 | uIU/mL | 0.40 - 4.50 | |
| CBC w Auto Diff | ||||
| WBC Count | 4.9 | K/uL | 4.0 - 11.0 | |
| RBC Count | L 3.46 | M/uL | 4.40 - 6.00 | |
| Hemoglobin | 10.4 | g/dL | 13.5 - 18.0 | |
| Hematocrit | L 31.4 | % | 40.0 - 52.0 | |
| MCV | 91 | fL | 80 - 100 | |
| MCH | 30.1 | pg | 27.0 - 33.0 | |
| MCHC | 33.1 | g/dL | 31.0 - 36.0 | |
| RDW | 14.4 | % | < 16.4 | |
| Platelet Count | 268 | K/uL | 150 - 400 | |
| Diff Type | Automated | |||
| Neutrophil | 66 | % | 49.0 - 74.0 | |
| Lymphocytes | L 20 | % | 26.0 - 46.0 | |
| Monocyte | 12 | % | 2.0 - 12.0 | |
| Eosinophil | 2 | % | 0.0 - 5.0 | |
| Basophil | 0 | % | 0.0 - 2.0 | |
| Abs. Neutrophil | 3.2 | K/uL | 2.0 - 8.0 | |
| Abs Lymphocyte | 1.0 | K/uL | 1.0 - 5.1 | |
| Monocyte | 0.6 | K/uL | 0.0 - 0.8 | |
| Eosinophil | 0.1 | K/uL | 0.0 - 0.5 | |
| Basophil | 0.0 | K/uL | 0.0 - 0.2 | |
| ESR | 19 | mm/hr | 0 - 20 | |
| Pantothenic Acid, B5 | 90 | ng/mL | < 275 | |
| Doctor's File Notes | History | Lab Test Results |
| Medication | Symptoms | Table of Contents |